Biomarkers of Response to Taxotere in Hormone-Refractory Prostate Cancer.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 29 May 2017
At a glance
- Drugs Docetaxel (Primary)
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
- 23 May 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Dec 2017.
- 04 Apr 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Feb 2017 as reported by ClinicalTrials.gov record.
- 04 Apr 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.